(E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol | 1075174-91-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol
• 英文别名: 3-amino-1-[3-[(E)-2-(2,6-dichlorophenyl)ethenyl]phenyl]propan-1-ol
• CAS: 1075174-91-2
• 化学式: C₁₇H₁₇Cl₂NO
• 分子量: 322.234
• InChiKey: JNCYMQSTWYVZCF-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol 、 二碳酸二叔丁酯 在 二氧化锰 silica gel 、 EtOAc-hexanes 作用下， 以 二氯甲烷 为溶剂， 反应 16.5h， 以afforded (E)-tert-butyl 3-(3-(2,6-dichlorostyryl)phenyl)-3-oxopropylcarbamate as an oil的产率得到(E)-tert-butyl 3-(3-(2,6-dichlorostyryl)phenyl)-3-oxopropylcarbamate
  参考文献：
  名称：

  STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS

  摘要：

  本发明通常涉及用于治疗神经退行性疾病和障碍的组合物和方法，特别是用于治疗眼科疾病和障碍。本文提供了包括但不限于苯乙烯衍生物化合物和含有这些化合物的组合物，这些化合物对于治疗和预防眼科疾病和障碍，包括年龄相关性黄斑退化（AMD）和Stargardt病都非常有用。

  公开号：

  US20120129860A1
• 作为产物：
  描述：

  3-[(E)-2-(2,6-dichlorophenyl)ethenyl]benzaldehyde 在 lithium aluminium tetrahydride 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 为溶剂， 反应 1.32h， 生成 (E)-3-amino-1-(3-(2,6-dichlorostyryl)phenyl)propan-1-ol
  参考文献：
  名称：

  WO2008/131368

  摘要：

  公开号：

文献信息

• Styrenyl derivative compounds for treating ophthalmic diseases and disorders
  申请人：Scott Ian Leslie

  公开号：US08653142B2

  公开（公告）日：2014-02-18

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明涉及一般用于治疗神经退行性疾病和疾病的组合物和方法，特别是用于治疗眼科疾病和疾病。本文提供了苯乙烯衍生物化合物，包括但不限于蒽醌衍生物化合物，以及包含这些化合物的组合物，可用于治疗和预防眼科疾病和疾病，包括年龄相关性黄斑部退化（AMD）和Stargardt病。
• Styrenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders
  申请人：Acucela Inc.

  公开号：US20150166494A1

  公开（公告）日：2015-06-18

  The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

  本发明涉及一般用于治疗神经退行性疾病和紊乱的组合物和方法，特别是用于治疗眼科疾病和紊乱。本文提供了包括但不限于苯乙烯衍生物化合物和含有这些化合物的组合物，这些化合物可用于治疗和预防眼科疾病和紊乱，包括老年性黄斑变性（AMD）和Stargardt病。
• Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
  申请人：Acucela Inc.

  公开号：US10730825B2

  公开（公告）日：2020-08-04

  Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.

  本文提供了治疗眼科疾病或病症的方法，例如与患者糖尿病相关的眼科疾病或紊乱。本文还提供了治疗早产儿视网膜病变的方法。此外，本文还提供了治疗患者湿性年龄相关性黄斑变性的方法。这些方法包括向有需要的患者施用本文公开的化合物，以抑制或减缓此类病症的一种或多种体征或症状。
• METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY
  申请人：Acucela Inc.

  公开号：EP2844636B1

  公开（公告）日：2020-04-22
• METHODS FOR THE TREATMENT OF DIABETIC RETINOPATHY AND OTHER OPHTHALMIC DISEASES
  申请人：Acucela Inc.

  公开号：US20140039048A1

  公开（公告）日：2014-02-06

  Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.